Match the following Hepatitis B serological and biochemical profiles to their most accurate clinical status.
- HBsAg (+), HBeAg (+), Anti-HBc IgM (+), Anti-HBs (-), ALT U/LAcute Hepatitis B infection
- HBsAg (+), HBeAg (-), Anti-HBc IgG (+), Anti-HBs (-), HBV DNA IU/mL, ALT U/LInactive chronic Hepatitis B phase
- HBsAg (+), HBeAg (-), Anti-HBc IgG (+), Anti-HBs (-), HBV DNA IU/mL, ALT U/LHBeAg-negative chronic Hepatitis B (precore/basal core promoter mutant)
- HBsAg (-), HBeAg (-), Anti-HBc IgG (+), Anti-HBs (+), ALT U/LResolved natural Hepatitis B infection
- HBsAg (-), HBeAg (-), Anti-HBc (-), Anti-HBs (+), ALT U/LImmunity due to Hepatitis B vaccination
Answer
The correct matches associate the distinct serological markers and biochemical findings to their corresponding Hepatitis B clinical states, specifically identifying the high-yield HBeAg-negative mutant strain through its high HBV DNA and elevated ALT despite negative HBeAg.
Hepatology serology interpretation relies on a sequential evaluation of surface antigen/antibody (current infection vs. immunity), core antibodies (acute vs. chronic vs. natural immunity), and e-antigen/DNA levels (viral replication activity). Incorporating ALT and HBV DNA is critical to clinically differentiate a benign inactive carrier phase from a highly pathogenic precore mutant strain.
Step-by-Step Solution
Key Concept
Interpretation of Hepatitis B serological markers (HBsAg, Anti-HBs, Anti-HBc, HBeAg) in conjunction with HBV DNA and ALT levels to distinguish among acute, chronic, precore mutant, inactive, and resolved/vaccinated clinical states.